Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...
We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...
While the needle remains the most common delivery vehicle for vaccines, a large number of patients suffer from needle phobia, making the intranasal delivery route a promising alternative to help boost ...